Clinical trial
Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3
NCT03746587 · ZevraDenmark, Industry · Terminated
Key facts
| NCT number | NCT03746587 |
|---|---|
| Title | Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3 |
| Official title | Multicentre Double-blinded, Randomized Placebo-controlled Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3 |
| Lead sponsor | ZevraDenmark, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gaucher Disease, Type 1, Type 3 |
| Intervention type | Drug |
| Interventions | Arimoclomol, Placebo oral capsule |
| Enrollment | 39 |
| Start date | Jun 6, 2018 |
| Primary completion | Apr 1, 2020 |
| Completion | Oct 15, 2021 |
| First posted | Nov 19, 2018 |
| Last update posted | Jan 11, 2023 |
| Countries | India |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: